Quantum Genomics announced the establishment of a U.S. Clinical Advisory Board of renowned cardiologists and cardiovascular researchers. The members will provide clinical and strategic guidance to the Company on the design of its hypertension clinical trial in the U.S. for lead product candidate QGC001, planned for 2017. The initial appointments to Quantum Genomics' Clinical Advisory Board include: Keith Ferdinand, MD — Professor of Medicine at the Tulane University School of Medicine; Henry Black, MD — Adjunct Clinical Professor of Medicine and member of the Section of Cardiology at the New York University School of Medicine, New York; Howard Dittrich, MD — Adjunct Professor of Medicine at the University of Iowa Carver College of Medicine and Chairman of the Board of Directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine. Dr. Henry Black is currently a member of the International Society of Hypertension and was a former President of the American Society of Hypertension. Dr. Howard Dittrich currently serves as an Entrepreneur-in-Residence for Frazier Healthcare Partners, Chief Medical Officer of Hawkeye Therapeutics, and consulting Chief Medical Officer at Leading Biosciences. He is a cardiologist with more than 20 years of experience in cardiovascular research and clinical development.

Additionally, the company announced its intention to establish a new office in New York City to advance its clinical programs and expand its presence in the United States. The launch of this New York office is expected to help strengthen Quantum Genomics' development activities in the U.S. and enable the company to more effectively engage with members of the U.S. medical and investment communities.